Tag Archives: CUREVAC’S NEXT-GEN COVID-19 VACCINE SHOWS PROMISE

GlaxoSmithKline and CureVac said a study on macaque monkeys showed their jointly-developed mRNA COVID-19 vaccine candidate to be “strongly improved” in protecting against the virus compared with CureVac’s first attempt. The encouraging news on its “second-generation” vaccine gave CureVac’s German-listed shares an 8% lift, as the stock gradually recovers from a slump in June when the German biotech company’s first …

Read More »